When to Consider Intralipid Therapy
The decision to use intralipid therapy in amniotic fluid embolism should be made promptly when standard resuscitative measures fail or if amniotic fluid embolism is suspected in the context of unexplained cardiovascular collapse, especially in a peripartum patient.
Dosing and Administration Protocol
Initial Bolus: Administer an initial bolus of 1.5 mL/kg of 20% intralipid over 1 minute.
Continuous Infusion: Follow with a continuous infusion of 0.25 mL/kg/min.
Re-Bolus: If the patient’s condition does not stabilize, a repeat bolus of intralipid may be given, not exceeding a total cumulative dose of 10 mL/kg in the first 30 minutes.
This dosing regimen is derived from protocols used in LAST, with adjustments made based on observed responses in amniotic fluid embolism case reports. It’s essential to have intralipid readily available in obstetric settings where amniotic fluid embolism is a risk, ensuring timely administration.
The intralipid dosing sequence described in this module, with the baseline labs to draw first and the cumulative dose cap.
Benefits of Intralipid Therapy for Amniotic Fluid Embolism
Rapid Hemodynamic Recovery: intralipid can produce rapid hemodynamic stabilization, even after prolonged cardiovascular collapse.
Readily Available: it is available in most hospital settings which facilitates its use in emergencies.
Cardioprotective Effects: Direct enhancement of myocardial function can support the heart during periods of severe stress.
Risks of Intralipid Therapy for Amniotic Fluid Embolism
Interference with Laboratory Tests: Intralipid can cause lipemia, leading to inaccurate laboratory results, particularly in coagulation studies, electrolyte measurements, hemoglobin concentration, and blood gas analysis. So, it is important to obtain essential blood tests (e.g., hemoglobin, electrolytes, coagulation profile) before intralipid administration to establish baseline values before initiating therapy.
Potential for Fat Overload Syndrome: High doses of intralipid may lead to fat overload syndrome, characterized by fever, hepatosplenomegaly, anemia, and thrombocytopenia, although this risk is minimal with short-term use in amniotic fluid embolism.
Limited Evidence: The use of intralipid in amniotic fluid embolism is supported primarily by anecdotal evidence and case reports. More extensive research is needed to validate its efficacy and safety.
| Step | Dose | Note |
|---|---|---|
| Initial bolus | 1.5 mL/kg of 20% intralipid over 1 minute | Give promptly when standard resuscitation fails or AFE is suspected in unexplained peripartum collapse |
| Continuous infusion | 0.25 mL/kg/min | Follows the initial bolus |
| Re-bolus | Repeat bolus if the patient does not stabilize | Do not exceed a cumulative 10 mL/kg in the first 30 minutes |
| Before administration | Draw baseline hemoglobin, electrolytes and coagulation profile | Lipemia distorts coagulation, electrolyte, hemoglobin and blood gas results |
| Watch for | Fat overload syndrome — fever, hepatosplenomegaly, anemia, thrombocytopenia | Risk is minimal with short-term use in AFE |
